email from Fred on the PRHi all, I asked Fred the following question:
Does this morning's PR about orphan status for PG to treat IPF mean that PLI is now looking at a two prong attack on IPF using both PG AND 4050 to treat IPF? This sounds new to me. Has this new approach been made public before?
Regards
Fred responded as follows: Hi .......,
This is indeed new info for the public. We have been waiting for a while for the orphan drug designation and finally received it.
If demonstrated efficacious in IPF, plasminogen would be used in IPF patients that are undergoing Acute exacerbations…just like patients with Acute Lung Injury…
In other words, plasminogen would be used in the Hospitals / ICUs whilst PBI-4050 would be chronic / once daily therapy.
When we say that “we are the company that can effectively address the entire healing process in a ground-breaking way using both small molecule drugs
and plasma protein therapies…” this is not a joke, we really do have a deep understanding of the healing process…
Cheers,
Fred
| Frederic Dumais |
| Directeur principal, Communications et relations avec les investisseurs, Senior Director, Communications and Investor Relations |
| |
| 440 Boul. Armand-Frappier |
| Laval, Quebec H7V 4B4 |
+1 450 781 0115
f.dumais@prometic.com |